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Leukotriene B4T lymphocytes are critical cells involved in allergy. Here, we report that the natural tetranortriterpenoid
gedunin impaired allergic responses primarily by modulating T lymphocyte functions. The intraperitoneal
(i.p.) administration of gedunin inhibited pleural leukocyte accumulation triggered by intra-pleural (i.pl.)
challenge with ovalbumin (OVA) in previously sensitized C57BL/6 mice; this inhibition was primarily due
to the impairment of eosinophil and T lymphocyte inﬂux. Likewise, i.pl. pre-treatment with gedunin inhibited
eosinophil and T lymphocyte migration into mouse lungs 24 h after OVA intra-nasal (i.n.) instillation. Pre-
treatment with gedunin diminished the levels of CCL2, CCL3, CCL5, CCL11, Interleukin-5 and leukotriene B4
at the allergic site. In vitro pre-treatment with gedunin failed to inhibit T lymphocyte adhesion and chemo-
taxis towards pleural washes recovered from OVA-challenged mice, suggesting that gedunin inhibits T lym-
phocyte migration in vivo via the inhibition of chemotactic mediators in situ. In vivo pre-treatment with
gedunin reduced the numbers of CD69+ and CD25+ T lymphocytes in the pleura and CD25+ cells in the tho-
racic lymph nodes 24 h after OVA i.pl. challenge. In accordance, in vitro treatment of T lymphocytes with
gedunin inhibited α-CD3 mAb-induced expression of CD69 and CD25, proliferation, Interleukin-2 production
and nuclear translocation of NFκB and NFAT. Notably, post-treatment of mice with gedunin reverted OVA-
induced lung allergic inﬂammation by decreasing the T lymphocyte and eosinophil counts and the levels of
eosinophilotactic mediators in bronchoalveolar lavage ﬂuid. Our results demonstrate a remarkable anti-
allergic effect of gedunin due to its capability to modulate T cell activation and trafﬁcking into the airways.
© 2012 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Allergy is characterized by an intense inﬂammatory response that
involves multiple mediators and cell types. Eosinophil inﬁltration to
sites of allergic inﬂammation correlates with the development of air-
way hyperresponsiveness and the clinical severity of allergic diseases,
such as asthma [1–4]. Indeed, eosinophil activation leads to the gen-
eration and release of lipid mediators and cytokines, which are crucial
in the development and maintenance of the allergic response [2,5–7].
Eosinophil trafﬁcking from the blood to inﬂamed tissue during the
allergic response is coordinated primarily by the eosinophilotactic
mediators interleukin (IL)-5 and chemokine (C-C motif) ligand 11
(CCL11)/eotaxin. The production of thesemediators is highly dependent
on T lymphocytes, which also accumulate in the allergic tissue [8–15].gia Aplicada, Departamento de
swaldo Cruz, Rua Sizenando
041‐250, Brazil. Tel.: +55 21
. Henriques).
Program in Cellular andMolec-
k.
evier OA license.T lymphocytes are centrally involved in the allergic response. During
the allergic response, T lymphocytes generate a wide range of cytokines
and chemokines that modulate other cell populations, including eosin-
ophils. Patients with asthma [16–18] and allergic rhinitis [19,20] pre-
sent elevated levels of the Th2 cytokines IL-4, IL-5 and IL-13 and the
eosinophilotactic chemokines CCL11 and CCL5, all of which are depen-
dent on T lymphocyte activity [13]. In this context, the impairment of
T lymphocyte functions is essential for controlling the allergic response.
Indeed, the inhibition of T lymphocyte accumulation in the airways of
asthma patients and experimental animals ameliorates airway allergic
inﬂammation [21–26] and diminishes eosinophil inﬁltrates in the
allergic tissue. Hence, impairing the production of soluble mediators
that activate T lymphocytes and orchestrate their migration into the
allergic tissue is a valuable strategy to control the allergic response.
We have previously described that a fraction containing
tetranortriterpenoid (TNTP) compounds extracted from the seeds
of Carapa guianensis Aublet (Meliaceae)—which contains gedunin
as one of the compounds—presented marked anti-allergic effects
in different in vivo models [27,28]. Our results support the eth-
nopharmacologic use of C. guianensis in Brazil and other countries
encompassing the Amazon rainforest and are in accord with the
knowledge that the medicinal properties of this species correlate
Fig. 1. Structure of gedunin.
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rine model of allergic pleurisy, we have shown that this fraction
of pooled TNTPs impairs allergen-induced eosinophilia, primarily
due to the inhibition of IL-5 and CCL11 [28]. We have also demon-
strated that pooled TNTPs inhibit the in vitro proliferation of T lym-
phocytes and the production of inﬂammatory mediators [30].
In the present report, we investigated the potential anti-allergic
effect of the TNTP gedunin contained in this fraction. We demonstrate
that gedunin presents an important anti-allergic activity in in vivo
models of allergic airway inﬂammation, which was achieved by
both pre- and post-treatments with gedunin. This anti-allergic effect
was shown to be mediated by the inhibition of chemotactic mediators
involved in T cell and eosinophil migration. Moreover, we show that
gedunin directly modulates T lymphocyte activation, which is crucial
for the development and maintenance of the inﬂammatory allergic
response.
2. Materials and methods
2.1. Animals
The C57BL/6mice (18–20 g) used in this studywere provided by the
Oswaldo Cruz Foundation breeding unit (Rio de Janeiro, Brazil). The an-
imals were caged with free access to food and fresh water in a room
with the temperature ranging from 22 to 24 °C and a 12 h light/dark
cycle. The animalswere housed at the Farmanguinhos experimental an-
imal facility unit until use. All experimental procedureswere performed
according to The Committee on Ethical Use of Laboratory Animals of
Fundação Oswaldo Cruz (FIOCRUZ, Brazil; license L-0004/08).
2.2. Materials
Endotoxin-free ovalbumin (OVA), dexamethasone, phosphate buff-
ered saline (PBS), Tween-20, o-phenylenediamine dihydrochloride
(OPD), fucoidan, ethylenedyaminetetracetic sodium salt (EDTA), percoll,
sodium citrate, HEPES, bovine serum albumin (BSA), phosphate citrate
buffer, 3,3'-Diaminobenzidine tetrahydrochloride hydrate (DAB) and
Hank's balanced salt solution (HBSS)were purchased from Sigma Chem-
ical Co. (St. Louis, MO, USA). Aluminum hydroxide was purchased from
EMS Sigma Pharma (São Paulo, Brazil). Puriﬁed anti-murine CCL2,
CCL3, CCL5 and CCL11 monoclonal antibodies (mAbs), biotinylated
anti-CCL2, anti-CCL3, anti-CCL5 and anti-CCL11 mAbs and recombinant
CCL2, CCL3, CCL5 and CCL11 were obtained from PharMingen (San
Diego, CA, USA). The leukotriene (LT)B4 enzyme immunoassay (EIA)
kit was obtained from Cayman Chemical (Ann Arbor, MI, USA). Anti-
murine interleukin (IL)-2 mAb, biotinylated anti-IL-2 polyclonal anti-
bodies (pAb), recombinant IL-2, anti-murine IL-5 mAb, biotinylated
anti-IL-5 pAb, recombinant IL-5, anti-murine tumor necrosis factor-α
(TNF-α) mAb, biotinylated anti-TNF-α pAb, recombinant mouse TNF-α
(rmTNF-α), Peridinin-chlorophyll-protein complex (PerCP)-conjugated
hamster IgG anti-murine CD3, ﬂuorescein isothiocyanate (FITC)-
conjugated hamster IgG anti-murine CD11b, phycoerytrin (PE)-
conjugated hamster IgG anti-murine CD25, FITC-conjugated rat IgG
anti-murine CD69, PerCP-conjugated IgG, PE-conjugated IgG and FITC-
conjugated IgG were all obtained from R&D Systems (Minneapolis,
MN, USA). Fetal bovine serum (FBS) was obtained from HyClone
(Logan, Utah, USA). Carboxyﬂuorescein diacetate-succinimidyl ester
(CFSE) was obtained from Invitrogen (Carlsbad, CA, USA) Rabbit anti-
mouse nuclear factor (NF)kB/p65 (C-20), goat anti-mouse nuclear factor
of activated T cells (NFAT), biotinylated goat anti-rabbit IgG and bio-
tinylated rabbit anti-goat IgG were obtained from Santa Cruz Biotechnol-
ogy, Inc. (Santa Cruz, CA, USA); and streptavidin-conjugated horseradish
peroxidase was purchased from Caltag Laboratories (Burlingame, CA,
USA). Endotoxin-free geduninwas purchased fromGaya Chemical Corpo-
ration (Gaylordsville, CT, USA) (Fig. 1). Gedunin purity (95%) was certi-
ﬁed by thin layer chromatography by Gaya Chemical Co. and by high-speed countercurrent chromatography (HSCC) (in a model HSCCC-
1000; Pharma-Tech Research Corp., Baltimore, Maryland, USA) at
Farmanguinhos Natural Product Laboratory.2.3. Treatments
Mice received an intraperitoneal (i.p.) injection of gedunin
(60–500 μg/kg) diluted in sterile PBS/0.001% Tween 20 or of dexa-
methasone (1 mg/kg) diluted in sterile PBS 1 h prior to or 1 h after
OVA stimulation. The same volume of vehicle was administered to
the control groups.2.4. Allergic pleurisy
Allergic pleurisy has been an established animal model to study the
allergic response, in which serum IgE levels and tissue eosinophilia are
increased, as previously reported by us and others [31–33]. For that,
mice were actively sensitized by a subcutaneous (s.c.) injection of
200 μl of a mixture of OVA (50 μg) and aluminum hydroxide (5 mg).
Fourteen days later, the mice were challenged with an intrapleural
(i.pl.) injection of OVA (12.5 μg/cavity) diluted in sterile PBS to a ﬁnal
volume of 100 μl. Sensitizedmice challengedwith vehicle alone (saline)
were used as the negative control group. Twenty-four hours after the
stimulus, the mice were euthanized by excess carbon dioxide inhala-
tion, and their thoracic cavities were rinsed with 1 ml of saline con-
taining EDTA (10 mM), pH 7.4. Thoracic lymph nodes were harvested
andmechanically dissociated into single-cell suspensions after centrifu-
gation (400×g for 10 min).2.4.1. OPW preparation
Cell-free pleural washes recovered from OVA-challenged mice
(OPW) were used as the stimulus in in vitro and in vivo assays. For
OPW preparation, 24 h after i.pl. OVA injection into sensitized mice
(OVA, 12.5 μg/cavity), the pleural cavities of the mice were washed
with 500 μl of saline/EDTA (10 mM), pH 7.4. Sensitized mice that
were injected with vehicle alone (saline) were used as the negative
control group (SPW). Pleural washes recovered from mice injected
with saline (SPW, n=10) or OVA (OPW, n=10) were pooled and
centrifuged (420 ×g for 10 min at 20 °C), and the cell-free superna-
tant was maintained at −20 °C until use.
Table 1
Effect of gedunin on T lymphocyte viability.
Vehicle 0.1 μM 1 μM 10 μM 100 μM 200 μM
T lymphocyte
viability (%)
100 100 100 100 100 95
Results are expressed as percentage of cell viability (%) from quadruplicate wells
(2×106 cells/well), after incubation of cells with gedunin for 20 h (37 °C, 5% CO2).
Cell viability was assessed using MTT assay, as described in Materials and methods.
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Fourteen days after active sensitization (50 μg OVA/5 mg alumi-
num hydroxide in 200 μl, s.c.), the mice were boosted by the same
mixture and route of administration. On days 21, 22 and 23, anesthe-
tized mice (ketamine [35 mg/kg]/xylazine [5 mg/kg], 100 μl i.p.) re-
ceived an intranasal (i.n.) dose of 100 μg OVA in 25 μl of saline
solution (or saline solution alone). Twenty-four hours after the last
challenge, the mice were euthanized and bronchoalveolar lavage
(BAL) ﬂuid was obtained via the tracheal cannula by gently washing
with 1 ml of saline containing EDTA (10 mM), pH 7.4. This method
was adapted from Fonseca et al. [34].
2.6. Leukocyte counts
Total leukocyte counts from pleural washes, BAL and thoracic
lymph nodes were determined using a Neubauer chamber, under an
optical microscope, after dilution in Turk ﬂuid (2% acetic acid). Pleural
T lymphocyte counts are reported as the number of cells per cavity.
The lymph node T lymphocyte counts are expressed as cells per mil-
ligram of lymphoid tissue.
2.7. Flow cytometric analysis
Leukocytes (106/100 μl) were labeled with the appropriate con-
centration of PerCP-conjugated anti-CD3 mAb, PE-conjugated anti-
CD25 mAb, FITC-conjugated anti-CD69 mAb, or PerCP-, PE- or FITC-
conjugated isotype antibodies for 30 min at 4 °C after an incubation
with rat serum to block non-speciﬁc binding. The cells were then
washed with PBS/0.1% azide and surface marker analysis was per-
formed using Cell Quest software on a FACSCalibur ﬂow cytometer
(Becton Dickinson, San Jose, CA, USA). At least 104 T lymphocytes
were acquired per sample. All data were collected and displayed on
a log scale of increasing ﬂuorescence intensity and are presented as
histograms. T lymphocyte numbers were determined after multiply-
ing the percentage of CD3+ cells by the total number of leukocytes.
2.8. Intracellular immunostaining
After surface marker staining, cells recovered from the pleural cavi-
ties ofmicewere ﬁxedwith 2%paraformaldehyde at 4 °C for 20 min and
incubatedwith 0.1% saponin in PBS/0.1% azide/10% FBS. For intracellular
staining of chemokines, anti-murine CCL2, CCL3 or CCL5 biotinylated
antibodies were added to the cell suspension and incubated at 4 °C for
30 min, followed by streptavidin-Cy-Chrome. The analysis was per-
formed using Cell Quest software on a FACSCalibur ﬂow cytometer
(Becton Dickinson, San Jose, CA, USA). CD11b+ cells withinmononucle-
ar cell gate (determined by FSC-H and SSC-H characteristics) were
speciﬁcally gated, and at least 104 cells were acquired per sample. The
counts are reported as the percentage of positive cells.
2.9. Quantiﬁcation of inﬂammatory mediators
CCL2/MCP-1, CCL3/MIP-1α, CCL5/RANTES, CCL11/eotaxin, IL-5 and
IL-2 levels were evaluated in cell-free pleural washes recovered from
sensitized C57BL/6 mice 24 h after OVA stimulation (12.5 μg/cavity,
OPW) or in the supernatant of α-CD3-stimulated T lymphocytes by
enzyme-linked immunosorbent assay (ELISA) using matched antibody
pairs from R&D Systems, according to the manufacturer's instructions.
IL-5, CCL5 and CCL11 were evaluated in BAL ﬂuid by cytometric beads
array (CBA, BD Pharmingen) on a FACSCalibur (BD) according to the
manufacturer's instructions. The LTB4 levels were measured by EIA in
24 h-OPW using a commercial kit (Cayman Chemical, Ann Arbor, MI)
according to the manufacturer's instructions. The results are expressed
as pg/ml or ng/ml based on a standard curve.2.10. Recovery of splenic T lymphocytes
Spleens recovered from euthanized C57BL/6 mice were dissected
and macerated in RPMI 1640 medium with Ca2+/Mg2+ containing
30 mM HEPES and 0.25% BSA, pH 7.4. The tissue was centrifuged
(420 ×g for 10 min at 20 °C), and the pellet was resuspended in 5 ml
of assay buffer (RPMI 1640 enriched with 10% FBS, 2 mM L-glutamine,
25 μg/ml gentamicin and 50 μM β-mercaptoethanol, pH 7.4). After cen-
trifugation (200 ×g for 10 min at 20 °C), the leukocyte pellet was
resuspended in 3 ml of assay buffer and submitted to a Histopaque-
1077 gradient (400 ×g for 30 min at 20 °C). T lymphocytes were isolat-
ed using a T cell enrichment column (R&D Systems, Minneapolis, MN,
USA) (>85% of CD3+ T lymphocytes). The viability of the T cellswas de-
termined by trypan blue exclusion under light microscopy (>95%).
2.11. Endothelial cell culture
The murine thymic endothelioma cell line tEnd.1 was grown
in RPMI 1640 supplemented with 10% FBS containing 25 μg/ml
of gentamicin. Adherent cells were detached by 5-min incubation
in 4 °C trypsin/EDTA solution, washed and counted under a light
microscope.
2.12. Cytotoxicity assay
The cytotoxicity of gedunin was determined in T lymphocytes re-
covered from C57BL/6 mouse spleens. Viable cells were seeded in a
ﬂat-bottomed 96-well plate (2×106 cells/well) and cultured for 1 h
(in 5% CO2 at 37 °C). The cells were cultured in the presence of differ-
ent concentrations of gedunin (10 to 200 μM) for 20 h and incubated
with a solution containing MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide] (5 mg/ml in saline; 22.5 μl/well) for
4 h. The supernatant was discarded, and dimethyl sulfoxide (DMSO;
150 μl/well) was added for solubilization of the formazan crystals.
The absorbance was measured at 540 nm (SpectraMax M5, Molecular
Devices, USA). The compound concentrations that induced≥10% cell
death were considered cytotoxic and were not used in the biological
assays (Table 1), as previously described [30].
2.13. Cell adhesion assay
tEnd.1 cells were cultured in RPMI 1640 medium supplemented
with 10% heat-inactivated FBS, 2 mM L-glutamine, 100 IU/ml penicillin,
and 100 μg/ml streptomycin. These cells were incubated at 37 °C in a
humidiﬁed incubator containing 5% CO2 and plated onto 24-well cul-
ture chambers (104 cells/well) (Nunc, Rochester, NY, USA) for 24 h.
Before each experiment, the tEnd.1 cells were stimulatedwith recombi-
nant mouse TNF-α (10 ng/ml) for 4 h. T lymphocytes recovered from
naïve C57BL/6 mice were pre-treated with fucoidan (25 μg/ml) or
gedunin (100 μM, 1 h) and then allowed to adhere to the tEnd.1 cul-
tures (50 T lymphocytes/tEnd.1) for 1 h. Non-adherent cells were gent-
ly washed away with phosphate-buffered saline (PBS), and the
remaining cells were subsequently ﬁxed in ethanol, stained with
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pus CK40, Japan). The number of adhered T lymphocytes per tEnd.1
cell was determined by direct counting. The data are expressed as an
index of adhesion (IA), with was calculated as follows: IA=(tEnd.1
with bound T lymphocytes)/Total tEnd.1 number x (T lymphocytes
bound to tEnd.1)/Total tEnd.1 number×100, as previously described
[30].
2.14. Chemotaxis assay
T lymphocytes recovered from naïve C57BL/6 mouse spleens were
resuspended in RPMI 1640 supplemented with 10% FBS and assayed
in a 48 well micro chemotaxis chamber (Neuroprobe Inc., Cabin John,
MD, USA). The bottom wells of the chamber were ﬁlled with 28 μl of
OPW or SPW, whereas the upper wells were ﬁlled with T lymphocytes
(105 cells; 50 μl) previously treated with gedunin (100 μM for 1 h). The
bottom and upper cells were separated by a 3 μm polycarbonate ﬁlter
(Nuclepore, Pleasanton, USA). The chamber was maintained in a hu-
midiﬁed incubator with 5% CO2 at 37 °C for 2 h. The number of mi-
grated cells was estimated under light microscopy. Chemotaxis was
calculated and expressed as the mean number of migrated cells in
ﬁve random high-power ﬁelds (HPFs) per well (in quadruplicate) [35].
2.15. In vitro stimulation of T lymphocytes
Anti-CD3mAb (10 μg/ml) was placed in each well of a 96 well plate
(Costar, Cambridge, MA, USA) at room temperature for 4 h. T lympho-
cytes recovered from naïve C57BL/6micewere incubatedwith gedunin
(100 μM), vehicle (DMSO 0.5%) or dexamethasone (5 nM) for 1 h andFig. 2. Effects of gedunin pre-treatment on pleural and lung accumulation of total leukocytes
challenge was given by i.pl. injection 1 h after i.p. treatment with gedunin (60–500 μg/kg). Lu
Dexamethasone was used as a reference drug. The results are expressed as themean±SEM fr
between the non-stimulated and stimulated group.subsequently cultured in the anti-CD3 mAb-coated wells at a concen-
tration of 105 cells/well in RPMI 1640 medium supplemented with
10% FBS (at 5% CO2 and 37 °C). After 24 h, the T cells were recovered
for ﬂow cytometry and western blot analysis.
For proliferation assays, another set of cells was labeled with CFSE
(1 μM/4×107 cells) and stimulated with the anti-CD3 mAb for 72 h.
After incubation, the cells were stained for surface markers, and cell di-
vision was assessed by the percentage of CFSE+ high cells (0 h) com-
pared to CFSE+ low cells (72 h) as assessed by ﬂow cytometry and
gated according to FL-1 intensity. The analyses were performed using
Cell Quest software on a FASCalibur ﬂow cytometer (Becton Dickinson,
San Jose, CA, USA). At least 104 gated CD3+ T lymphocytes were ac-
quired per sample.
2.16. Preparation of nuclear extracts and immunoblotting
Nuclear extracts were obtained from T lymphocytes previously
treatedwith gedunin (100 μMfor 1 h at 37 °C and 5%CO2) and stimulat-
ed with anti-CD3 mAb (10 μg/ml for 24 h) in vitro. Cells were lysed in
ice-cold buffer A (10 mM HEPES, pH 7.9; 10 mM KCl; 0.1 mM EDTA;
0.1 mM EGTA; 1 mM dithiothreitol and 0.5 mM PMSF), and after
15 min of incubation on ice, Nonidet P-40 (NP-40) was added to a
ﬁnal concentration of 0.5% (v/v). Nuclei were collected by centrifuga-
tion (14,000 g for 5 min at 4 °C). The nuclear pellet was suspended in
ice-cold buffer C (20 mM HEPES, pH 7.9; 400 mM NaCl; 1 mM EDTA;
1 mM EGTA; 1 mM dithiothreitol; 1 mM PMSF; 1 mg/ml pepstatin;
1 mg/ml leupeptin; and 20% glycerol [v/v]) and incubated for 30 min.
Nuclear proteins were collected (supernatant after centrifugation at
14,000 ×g for 10 min at 4 °C). The total protein content in the nuclear(A, D), mononuclear cells (B, E) and eosinophils (C, F) 24 h after OVA challenge. Pleural
ng instillation was performed in mice treated with a single dose of gedunin (500 μg/kg).
om at least 6 animals per group. * indicates statistically signiﬁcant differences (p≤0.05)
Fig. 3. Effects of pre-treatment with gedunin (500 μg/kg, i.p.) on the numbers of T lymphocytes in pleural washes (A) and BAL ﬂuid (B) 24 h after OVA challenge (i.pl. or i.n., re-
spectively). Dexamethasone was used as a reference drug. The results are expressed as the mean±SEM from at least 6 animals per group. * indicates statistically signiﬁcant differ-
ences (p≤0.05) between the non-stimulated and stimulated group. Representative dot plots showing the percentage of CD3+ T lymphocytes are displayed in the right panel.
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denatured in Laemmli sample buffer (50 mMTris–HCl, pH 6.8; 1% sodi-
um dodecyl sulfate [SDS]; 5% 2-mercaptoethanol; 10% glycerol and
0.001% bromophenol blue) and heated at 95 °C for 3 min. The samples
(10 μg of total protein) were resolved by 12% SDS-polyacrylamide gel
electrophoresis (PAGE) and the proteins were transferred to nitrocellu-
lose membranes (Hybond-C Pure, Amersham Pharmacia Biotech, San
Francisco, CA, USA). The membranes were blocked with Tween-PBS
(0.5% Tween-20) containing 2% BSA and probed with the speciﬁc pri-
mary monoclonal antibodies anti-NFAT and anti-NFκB/p65 (1:500,
Santa Cruz, CA, USA). After extensive washing in Tween-PBS, the nitro-
cellulose membranes were incubated with an anti-goat or an anti-
rabbit IgG biotin-conjugated antibody (1:1000; Sigma) for 1 h, followed
by streptavidin-conjugated horseradish peroxidase (1:1000; Caltag
Laboratories, Burlingame, CA, USA). Immunoreactive proteins were vi-
sualized by 3,3′-diaminobenzidine (DAB, Sigma) staining. The bands
were quantiﬁed by densitometry, using ImageJ (public domain) soft-
ware programs.
2.17. Statistical analysis
The data are reported as the mean±standard error of the mean
(SEM) and were statistically analyzed by analysis of variance
(ANOVA), followed by the Student–Newman–Keuls test or Student's
t-test. Values of p≤0.05 were regarded as signiﬁcant.3. Results
3.1. Gedunin pre-treatment inhibits leukocyte migration during allergic
airway inﬂammation
The i.pl. injection of OVA (12.5 μg/cavity) induced an intense ac-
cumulation of total leukocytes in the pleural cavity of C57BL/6 mice,
due to the migration of mononuclear cells and eosinophils (Fig. 2A–
C). Pre-treatment with gedunin (from 60 to 500 μg/kg, i.p.) revealed
that the highest dose administered was able to inhibit the total leu-
kocyte and eosinophil accumulation, but failed to inhibit the migra-
tion of mononuclear cells. Dexamethasone pre-treatment (1 mg/kg,
i.p.), which was used as a reference drug, diminished the numbers
of all cell populations. Importantly, the range of gedunin doses used
in this experiment was determined based on a previous in vivo dose
response experiment (performed on a log scale from 50 μg/kg to
50 mg/kg of gedunin, i.p.); the range of 60 to 500 μg/kg was chosen
to be further assayed (Supplemental Fig. 1A). OVA instillation
(100 μg, i.n.) also triggered an accumulation of total leukocyte, mono-
nuclear cells and eosinophils in the lungs of previously sensitized
mice (Fig. 2D–F). Similar to its effect on allergic pleurisy, i.p. pre-
treatment with gedunin diminished OVA-induced total leukocyte
and eosinophil counts in BAL ﬂuid recovered within 24 h.
Among pleural leukocytes, OVA challenge triggered an intense in-
ﬂux of CD3+ T lymphocytes into the mouse pleural cavities and lungs
Fig. 4. Effects of gedunin pre-treatment on CCL2 (A), CCL3 (B), CCL5 (C), CCL11 (D), IL-5 (E) and LTB4 (F) generation in the pleural cavities of challenged mice. The levels of che-
motactic mediators were determined in pleural washes recovered 24 h after saline or OVA (12.5 μg/cavity, i.pl.) stimulation by ELISA (A–E) and EIA (F). Dexamethasone was used as
a reference drug. The effect of gedunin on chemokine production by pleural macrophages is demonstrated as percentages of CCL2+, CCL3+ and CCL5+/CD11b+ cells recovered from
mouse pleural cavities 6 h after i.pl. injection of OVA (G). The results are expressed as the mean±SEM from at least ﬁve animals per group. * indicates statistically signiﬁcant dif-
ferences (p≤0.05) between the non-stimulated and stimulated animals, whereas “+” indicates signiﬁcant differences between the stimulated and treated groups.
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with gedunin (500 μg/kg) or dexamethasone (1 mg/kg, i.p.) 1 h
prior to challenge. Representative dot plots showing the percentage
of CD3+ T lymphocytes among total leukocytes are displayed in the
right panel.
3.2. Gedunin pre-treatment inhibits the production of chemotactic medi-
ators at the allergic site
To evaluatewhether gedunin reduced the in vivomigration of eosin-
ophils and T lymphocytes by inhibiting the production of chemotactic
mediators at the inﬂammatory site, the levels of CCL2, CCL3, CCL5,
CCL11, IL-5 and the lipid mediator LTB4 were evaluated in pleural
washes recovered 24 h after OVA challenge (12.5 μg/cavity). OVAFig. 5. Effects of gedunin on T lymphocyte adhesion to endothelial cells (A). T lymphocyte
gedunin and allowed to adhere to previously stimulated tEnd.1 cells (50 T lymphocytes/tE
an association index calculated as described in Materials and methods. The effect of gedu
for 1 h and allowed to migrate towards OPW for 2 h in a chemotaxis chamber. The migrate
in vivo T lymphocyte inﬂux into mouse pleural cavities (C). C57BL/6 mice were pre-treate
assessed 24 h after OPW injection. * indicates statistically signiﬁcant differences (p≤0.05)challenge triggered increased production of these mediators, whereas
pre-treatment with gedunin (500 μg/kg, i.p.) signiﬁcantly reduced the
levels of all of the evaluated mediators (Fig. 4A–F).
Resident macrophages are known to be a major source of
lymphotactic chemokines in the mouse pleura during the allergic re-
sponse [31]. We therefore investigated by intracellular staining
whether gedunin pre-treatment modulates chemokine production
by pleural macrophages recovered from the mouse pleura 6 h after
OVA challenge, which is a time point at which T lymphocyte and eosin-
ophil numbers are not signiﬁcantly increased. As shown in Fig. 4G,
OVA challenge induced the production of CCL2, CCL3 and CCL5 by
CD11b+macrophages, and this phenomenonwas reduced by gedunin
pre-treatment. These results show that the inhibition of T lymphocyte
accumulation by gedunin depends, at least in part, on the reduction ofs recovered from C57BL/6 mice were pre-incubated for 1 h with medium, fucoidan or
nd.1) for 1 h. Fucoidan was used as the positive control. Adhesion was quantiﬁed by
nin on in vitro T cell chemotaxis (B). Lymphocytes were pre-incubated with gedunin
d cells were counted under light microscopy. The effects of gedunin on OPW-induced
d with gedunin 1 h before the challenge with OPW (i.pl.). T lymphocyte counts were
between the non-stimulated and stimulated groups.
Fig. 6. Effects of gedunin pre-treatment (500 μg/kg, i.p.) on T lymphocyte activation in the mouse pleural cavities and thoracic lymph nodes. (A–B) Representative dot plots dem-
onstrate the percentage of expression of CD69 and CD25 in pleural CD3+ T lymphocytes 24 h after OVA stimulation. Dexamethasone was used as a reference drug. (C) CD3+ T lym-
phocyte counts per mg of thoracic lymph nodes. The data represent the mean±SEM from six animals per group. * indicates statistically signiﬁcant differences (p≤0.05) between
the non-stimulated and stimulated animals, whereas “+” indicates signiﬁcant differences between the stimulated and treated groups. (D) Representative dot plots of CD25+/CD3+
T lymphocytes 24 h after OVA-stimulation in the thoracic lymph nodes were obtained by ﬂow cytometry.
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allergic tissue.
3.3. Gedunin fails to inhibit T lymphocyte adhesion and chemotaxis in
vitro
Because T lymphocytes are centrally involved in the modulation
of other cell populations that participate in the allergic response,
the direct effect of gedunin on T lymphocytes was assessed. The
pre-incubation of T lymphocytes with gedunin (100 μM, 1 h before
the stimulus) failed to inhibit their adhesion to rmTNF-α-primedendothelial cells (Fig. 5A). In contrast, pre-treatment with fucoidan, a
carbohydrate that blocks selectins, inhibited T cell adhesion to endothe-
lial cells. In accord with these data, the pre-incubation of T lymphocytes
with gedunin (100 μM, 1 h before the stimulus) failed to impair T lym-
phocyte chemotaxis towards cell-free pleural washes recovered from
OVA-challenged mice (OPW), which contains chemotactic mediators
(as shown in Fig. 3) (Fig. 5B). Pre-incubation of cells with DMSO did
not induce any effect on T lymphocyte adhesion or chemotaxis (data
not shown).
OPW has been shown to trigger leukocyte migration when injected
into mouse pleural cavities [36]. To conﬁrm whether the lack of
Fig. 7. Effects of gedunin on T lymphocyte activation in vitro. Gedunin (100 μM, 1 h before stimulation) pre-treated lymphocytes were cultured in α-CD3 mAb-coated wells for 24 or
72 h. (A) and (B) show the percentages and mean ﬂuorescence intensity (MFI) of CD69 and CD25 expression in CD3+ T lymphocytes 24 h after OVA i.pl. stimulation, respectively.
(C) and (D) show the effect of gedunin on T lymphocyte proliferation assessed 72 h after α-CD3 mAb stimulation by CFSE staining and on IL-2 levels in the supernatant of α-CD3
mAb stimulated lymphocytes, respectively. The data represent the mean±SEM from quadruplicate wells per group. * indicates statistically signiﬁcant differences (p≤0.05) be-
tween the non-stimulated and stimulated groups, whereas+indicates signiﬁcant differences between the stimulated and treated groups. (E) The effects of gedunin on nuclear lo-
calization of NFAT and NFκB (p65) after α-CD3 mAb stimulation. NFAT and NFκB protein levels were determined in nuclear extracts of T lymphocytes pre-treated with gedunin or
dexamethasone and stimulated with α-CD3 mAb-coated wells for 24 h. Densitometric analysis is shown in the graphs. The results are expressed as the mean±SEM from triplicate
wells per group. * indicates statistically signiﬁcant differences (p≤0.05) between the non-stimulated and stimulated groups, whereas+indicates signiﬁcant differences between
the stimulated and treated groups.
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Fig. 8. Effects of gedunin post-treatment (500 μg/kg, i.p.) on T lymphocyte (A) and eosinophil numbers (B) in BAL ﬂuid 24 h after OVA challenge (100 μg, i.n.). IL-5, CCL5 and CCL11
(C, D and E) levels were determined by ELISA in BAL recovered 24 h after saline or OVA i.n. instillation. Dexamethasone was used as a reference drug. The results are expressed as
the mean±SEM from at least 6 animals per group. * indicates statistically signiﬁcant differences (p≤0.05) between the non-stimulated and stimulated groups.
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effect involving adhesion molecules or cell motility pathways, we per-
formed an in vivo adoptive transfer of OPW into gedunin pre-treated
mice (500 μg/kg, i.p.). As expected, OPW i.pl. injection triggered a signiﬁ-
cant increase in CD3+ T lymphocyte numbers in the mouse pleural cavi-
ties comparedwithmice injectedwith cell-free pleural washes recovered
from saline-injected mice (SPW) (Fig. 5C). In vivo pre-treatment with
gedunin (500 μg/kg, i.p.) failed to inhibit OPW-induced CD3+ T lympho-
cyte accumulation. Taken together, these results suggest that gedunin
does not prevent T cell adhesion or mobilization towards chemotactic
mediators in vivo.
3.4. Gedunin modulates CD69+ and CD25+ expression by T lymphocytes
in vivo
Flow cytometric analysis showed that OVA i.pl. challenge
(12.5 μg/cavity) triggered increased percentages of CD3+ T lympho-
cytes expressing CD69 and CD25 (Fig. 6A–B) 24 h after stimulation.
Pre-treatment with gedunin (500 μg/kg, i.p.) reduced the percentage
of pleural CD3+ T lymphocytes expressing these two surface mole-
cules, as did pre-treatment with dexamethasone (1 mg/kg, i.p.).
OVA i.pl. challenge induced an increase in T lymphocyte numbers in
mouse thoracic lymph nodes at 24 h after stimulation, which was
inhibited by pre-treatment with gedunin or dexamethasone (Fig. 6C).
These cells also presented an activated phenotype by expressing CD25
and CD69 (Fig. 6D and data not shown). Pre-treatment with gedunin
was able to diminish the percentage of CD3+ CD25+ lymphocytes re-
covered from the thoracic lymph nodes (Fig. 6D); however, no changes
in CD69 expression were observed (data not shown).
3.5. Gedunin modulates T lymphocyte activation in vitro
The in vitro stimulation of T lymphocytes with α-CD3 mAb
(10 μg/ml) triggered an increase in the percentages of CD69+ and
CD25+ T lymphocytes, which was reduced by pre-incubation withgedunin (100 μM for 1 h before stimulation) (percentages are dem-
onstrated in representative histograms in Fig. 7A–B). Gedunin pre-
treatment also reduced the mean ﬂuorescence intensity (MFI) of
CD69 and CD25 (Fig. 7A–B), which is demonstrated in representa-
tive histograms of CD69 and CD25 expression, respectively. Pre-
treatment with dexamethasone (Dexa; 5 nM) also diminished
CD69 and CD25 expression. The incubation of T lymphocytes with
DMSO (0.5%) did not induce any change in CD25 and CD69 expres-
sion (data not shown). In accord with these data, gedunin pre-
treatment blocked α-CD3 mAb-induced T lymphocyte proliferation
within 72 h as assessed by CFSE staining (Fig. 7C) and blocked IL-2
production (Fig. 7D).
To investigate whether the effect of gedunin on T lymphocyte ac-
tivation correlated with modulation of transcriptional factors, the
protein levels of NFAT and NFκB/p65 were determined by western
blot analysis in nuclear extracts of α-CD3 mAb-stimulated T lym-
phocytes that were pre-treated or not pre-treated with gedunin.
Fig. 7E shows that α-CD3 mAb stimulation enhanced the levels of
NFAT and NFκB/p65 in T cell nuclei (lane 2) compared to non-
stimulated lymphocytes (lane 1). The translocation of NFAT and
NFκB/p65 was signiﬁcantly inhibited by dexamethasone (5 nM)
and by gedunin (100 μM) pre-treatment (lanes 3 and 4, respectively).
Densitometric analysis of the bands is shown in the graphs below
(Fig. 7E). These results demonstrate that, even though gedunin does
not inhibit cell mobilization, it directly modulates multiple features of
T lymphocyte activation.3.6. Post-treatment with gedunin inhibits lung allergic inﬂammation
The post-treatment of mice with gedunin (500 μg/kg i.p., 1 h
after antigenic challenge) was able to revert OVA-induced (100 μg,
i.n.) parameters of lung allergic inﬂammation, including decreased
T lymphocyte and eosinophil counts in BAL ﬂuid (Fig. 8A–B). Similar
to the results obtained with pre-treatment, post-treatment with
gedunin also diminished the levels of eosinophilotactic mediators
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gedunin might present therapeutic beneﬁts for the treatment of airway
inﬂammatory diseases by modulating T lymphocyte activation.
4. Discussion
T lymphocytes are crucial for immunity against allergen-induced
diseases in atopic individuals and experimental animals [reviewed
in 37]. Here, we show that the natural TNTP gedunin inhibits allergic re-
sponses primarily bymodulating T lymphocyte functions and inhibiting
allergic eosinophilia.
Using two different models of airway allergic inﬂammation affect-
ing the pleura and lungs of sensitized mice, we demonstrate that
gedunin presents a remarkable anti-allergic effect that is comparable
to dexamethasone. Noteworthy, it has been previously published that
gedunin did not trigger toxic effects (including alterations in body
weight, organ weight and liver enzyme levels) when administrated
via different routes into mouse [38,39]. When administered by either
intraperitoneal or oral (Supplemental Fig. 1A, B) routes, gedunin was
able to inhibit leukocyte migration to challenged tissue and to reverse
the already established airway inﬂammation. Notably, the anti-
allergic property of gedunin seems to require the modulation of T
cell functions. The ﬁrst evidence of this requirement came from the
ability of gedunin to inhibit the generation of chemokines and lipid
mediators known to recruit and activate T lymphocytes in the tissue
(and consequently, to reduce T cell inﬁltrates); furthermore, gedunin
was able to directly inhibit T cell functions.
T lymphocyte migration towards a chemotactic gradient is a
multistep process that is precisely regulated by interactions of adhe-
sion molecules with their cognate receptors expressed on vascular
endothelium. Chemokines, such as CCL2, CCL3, CCL5 and LTB4 are
important mediators of T cell inﬂux into sites of inﬂammation,
including the airways [40–44], in which their production increases
during allergic responses, such as asthma [13,44–46]. In vivo pre-
treatment with gedunin reduced the in situ production of these media-
tors; however, this pre-treatment failed to interfere with T lymphocyte
adhesion to endothelial cells and chemotaxis. This assumption was
reinforced by the ﬁnding that the i.pl. injection of OPW (which contains
lymphotactic mediators, including CCL2, CCL3, CCL5 and LTB4) into
gedunin-pre-treated mice induced pleural accumulation of T lympho-
cytes to the same extent as in non-treated OPW-injected mice. There-
fore, gedunin inhibits in vivo T cell migration due to the inhibition of
chemotactic mediators in situ but not due to lymphocyte-endothelium
interactions. By inhibiting the generation of lymphotactic mediators,
the anti-allergic effect of gedunin seems to occur primarily via the im-
pairment of T cells.
In addition to preventing T lymphocyte inﬂux by blocking the
production of mediators with lymphotactic activity by resident
macrophages, gedunin also inhibits key parameters of T cell activa-
tion, such as the expression of CD69 and CD25 molecules, prolifera-
tion, production of IL-2 and translocation of the transcriptional
factors NFκB and NFAT. It is important to note that these effects
were observed in vitro, but gedunin treatment also resulted in di-
minished numbers of activated T lymphocytes in draining lymph
nodes and in the allergic tissue. During allergic responses, the num-
ber of T cells increase in the lymph nodes, as a consequence of an-
tigen presentation and clonal expansion, which is followed by the
migration of antigen-speciﬁc T lymphocytes into the inﬂamed site
[47,48]. Resident T cells are activated at the site of allergen deposi-
tion and mediate the local response to allergen, which is ampliﬁed
by the arrival of new T lymphocytes in the target tissue [49–51].
Challenged mice treated with gedunin presented similar numbers
of CD25+ (sal: 1.14±0.42×104 cells; OVA: 3.00±0.9×104 cells;
gedunin: 1.64±0.7×104 cells; n=6 in each group) and CD69+ T
lymphocytes (sal: 0.26±0.09×104 cells; OVA: 0.79±0.02×104
cells; gedunin: 0.40±0.09×104 cells; n=6 in each group) in thepleura of naïve mice, which suggests that either resident or newly
arrived T lymphocytes are not activated. Therefore, the inhibition
of T cell activation by gedunin treatment, both in the pleura and in
the draining thoracic lymph nodes of challenged mice, is noticeable.
In the draining lymph nodes, gedunin treatment reduced the num-
ber of CD3+ T lymphocytes and of CD25+CD3+ cells, suggesting
that in vivo blockade of T cell activation and expansion in secondary
lymphoid organs by the TNTP might occur. The hypothesis that treat-
mentwith gedunin affects T cell proliferation in vivo is supported by the
ﬁnding that gedunin inhibited IL-2 production by α-CD3-stimulated T
lymphocytes in vitro. IL-2 is a major cytokine that is involved in the
proliferation and differentiation of T lymphocytes and is crucial for
clonal expansion [52]. Such an effect seems tightly correlated with
the ﬁnding that gedunin blocked the nuclear translocation of tran-
scription factors required for cellular activation, among which NFκB
and NFAT can be highlighted [53]. NFκB and NFAT regulate the
expression of many genes involved in inﬂammation, including IL-2
[53]. NFAT is a transcription factor that is predominantly found in T
lymphocytes and regulates the expression of several cytokines (such
as IL-2, IL-4 and IL-5), by interactingwith AP-1 and forming a transcrip-
tional complex. As demonstrated for corticosteroids [54,55], gedunin
also inhibited nuclear translocation of NFAT and NFκB. Through
this inhibition, gedunin blocked the synthesis of IL-2 and conse-
quently the upregulation of CD25 (α-chain of IL-2 receptor), this
relationship has been shown to occur in a positive loop [56–58]. By
blocking the nuclear translocation of these two important transcrip-
tion pathways, attention is brought to the anti-inﬂammatory effect
of gedunin.
Eosinophilia is a common manifestation of late-phase allergic
inﬂammation and has been correlated with tissue damage. Eosino-
phil recruitment to an allergic site is coordinated by the generation
of chemotactic mediators, primarily T lymphocytes and macro-
phages [8–15]. Glucocorticoids, such as dexamethasone, have
been extensively used to treat allergic diseases such as asthma.
Glucocorticoid induction of eosinophil apoptosis has been pro-
posed as a key mechanism to reduce tissue and circulating eosino-
phil numbers [59–63]. Our results clearly demonstrate that gedunin-
induced eosinophil arrest is a result of the impairment of the T
cell-dependent eosinophilotactic mediators IL-5, CCL11 and CCL5,
even though gedunin also presents direct effects on isolated eosinophils
(impairing chemotaxis), as we have previously demonstrated [30]. The
ability of gedunin to revert eosinophil accumulation in the lungs might
also be a result of the arrested production of eosinophilotactic media-
tors because, as our group has demonstrated, gedunin does not induce
eosinophil death in vitro [30].
Notably, gedunin from C. guianensis and other species has been
demonstrated (by us and other authors) to exhibit immunomodu-
latory, anti-malarial and anti-cancer activities [30,64–66]. The
anti-proliferative activity of gedunin observed against tumor cell
lines has been demonstrated to be mediated through modulation
of heat shock protein 90 (HSP90) [67,68]. Indeed, the mechanism
of action of gedunin has been well established to be mediated by
modulation of HSP90 [69], which is a chaperone involved in folding
and conformational regulation of several client proteins [70]. In ad-
dition to their beneﬁts against cancer, HSP90 inhibitors can be useful as
anti-inﬂammatory compounds; accumulating evidence has suggested a
pro-inﬂammatory role of HSP90 in several experimental models of in-
ﬂammation, including lung inﬂammation [71–76]. In vivo treatment
with HSP90 inhibitors has been shown to prevent the activation of tran-
scriptional factors, the production of various inﬂammatory mediators
and leukocyte activation and migration in vitro and in vivo [74]. There-
fore, the anti-allergic and immunomodulatory effects of gedunin
are likely to be a consequence of HSP90 inhibition, which correlates
well with the pleiotropic effects of gedunin that are similar to those de-
scribed for HSP90 inhibitors; these effects include the inhibition
of cell proliferation, NFκB translocation, chemokine production and
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addressed in further studies.
Taken together, our results demonstrate a remarkable anti-
allergic effect of gedunin due to its ability to modulate T lympho-
cyte activation and trafﬁcking into the airways. In addition, these
data highlight the importance of further study of the druggability
and pharmacophoric properties of gedunin and bring to light the
knowledge that gedunin might represent a potential therapeutic
tool to suppress allergic features and control allergic diseases.
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